BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors - 2See tonight’s solar storm unfold across the world
- 3Outside Lovers' Decision: Favored Climbing Rucksacks
- 4Washington resident contracts bird flu, first human case in U.S. since February
- 5Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Tremendous Spelunking: Cool Caverns All over the Planet
- The Best Computer games Ever
- IDF carried out mission to locate former hostage Avera Mengistu a day before Oct. 7
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- NASA says Maven spacecraft that was orbiting Mars has gone silent
- Vacuum Cleaners That Are Not difficult To Use For Home
- Former hostage Eitan Mor on Hamas: ‘They will not give up until the last Israeli is gone'
- Must-See Attractions in Australia
